Cassava Sciences Inc SAVA shares are trading lower by 20% at $108 Thursday afternoon after the company reported biomarker data from an open-label study of simufilam, its investigational drug for the treatment of Alzheimer's disease.
"We are very pleased with the overall consistency of data," said Remi Barbier, President & CEO in a press release.
"Simufilam improved cognition, biomarkers and behavior, a triple-win for study participants. These clinical data combined with a clean safety profile and easy oral administration suggest highly encouraging and durable treatment effects for people living with Alzheimer's disease."
Cassava Sciences is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease.
Cassava Sciences has a 52-week high of $146.06 and a 52-week low of $2.78.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
